Introduction
============

Brain aging in most cases is characterized by cognitive deficits and a central cholinergic hypofunction ([@b7]). Alzheimer's disease (AD), a neurodegenerative disorder, is characterized by loss of memory and other cognitive abilities. It is also characterized by a prominent loss of cholinergic neurons in the basal forebrain ([@b23]), leading to decreased amounts of acetylcholine and decreased activities of cholinacetyltransferase (ChAT) and acetylcholinesterase (AChE) in almost the entire neocortex ([@b21]). The observed association between the loss of cholinergic neurons, receptors, reduction of cholinergic markers, cognitive and executive function impairments in AD was the base for the development of cholinergic hypothesis ([@b6]) and the introduction of AChE inhibitors as the main therapeutic approach for this disease. Rivastigmine is a second-generation carbamatebased pseudo-irreversible AChE and butyrylcholinesterase (BuChE) inhibitor, indicated for treatment of mild to moderate AD ([@b2]; [@b20]; [@b33]; [@b13]; [@b100]; [@b38] or for patients with rapid disease progression ([@b34]). As the disease and age progress, significant loss of other neurons (noradrenergic, dopaminergic) is observed as well ([@b24]; [@b95]). The pathology of the disorder may involve oxidative stress and accumulation of free radicals, leading to excessive lipid peroxidation and neuronal degeneration in the brain ([@b93]; [@b95]; [@b76]). Selegiline, (-)deprenyl, an irreversible monoamineoxidase-B (MAO-B) inhibitor, has been used in depression and in Parkinson's disease in combination with L-dopa ([@b8]; [@b60]; [@b52]; [@b72]; [@b50]). Selegiline enhances the release of dopamine, blocks the reuptake of dopamine and produces an amphetamine-like effect ([@b30]). Pretreatment with selegiline can protect neurons against a variety of neurotoxins as MPTP, DSP-4, 5,6-dihydroserotonin and AF64A, which damage dopaminergic, adrenergic, serotonergic, and cholinergic neurons respectively ([@b109]; [@b79]; [@b64]; [@b68]). In patients with moderate impairment from AD, treatment with selegiline slowed the progression of disease ([@b83]; [@b35]; [@b51]). However, according to recent data from a meta-analysis, selegiline significantly improved cognition and activities of daily living at an earlier time point, but not at a later assessment time ([@b112]; [@b10]). Selegiline prevents the effects of oxidative stress in a variety of models both in vitro and in vivo ([@b114]).

The underlying mechanism of the beneficial effect of selegiline on neuronal function is believed to be associated with enhanced activity of free radical scavenging enzymes ([@b15]; [@b50]; [@b49]), diminished production of hydrogen peroxide through MAO-B inhibition ([@b18]; [@b98]), some trophic-like effects that increase the survival of degenerating motoneurons ([@b45]), restoration of ChaT reduced activity ([@b55]), the number of neurons in the hippocampus ([@b49]), or enhancement of neuroplastic status ([@b70]). Recently [@b75] also reported an in vitro antiamyloidogenic activity of selegiline.

We have previously shown that the administration of selegiline in a dose of 0.25 mg kg^-1^ rat/other day for 50 days in old rats increased whole brain TAS, stimulated (Na^+^, K^+^)-ATPase activity and although it increased AChE activity, it improved the learning performance of aged rats ([@b14]).

The (Na^+^, K^+^)-ATPase, or Na^+^ pump, is an energy transducting ion pump first described by Skou in 1952 ([@b92]). In recent years, research on (Na^+^, K^+^)-ATPase revealed that interactions of (Na^+^, K^+^)-ATPase with other proteins not only are important for regulation of pumping function, but also make it possible for the enzyme to function as a single transducter ([@b113]). Long-term pharmacological interruption of cholinergic transmission can decrease the postsynaptic membrane potential by altering (Na^+^, K^+^)-ATPase activity. This can be seen as a decline in \[^3^H\] ouabaine binding ([@b43]). Age-associated impairments in a test of attention and evidence of involvement of cholinergic systems was referred by [@b46]. It is known that inhibition of (Na^+^, K^+^)-ATPase induces neurotransmitter release in several experimental models ([@b81]). Furthermore, studies suggest that (Na^+^, K^+^)-ATPase might play a role on memory formation ([@b27]). According to [@b39] (Na^+^, K^+^)-ATPase is a particular age-related enzyme. The (Na^+^, K^+^)-ATPase activity is lower in all plasma membrane subfractions (rat frontal cerebral cortex) at 22 months of age, than in 5 months (where reduction is already evident at 10 months of age). Similar reductions in (Na^+^, K^+^)-ATPase activity were observed by [@b48] in different brain regions of 24-month-old rats. However, old age and selective loss of cholinergic basal frontal cells did not significantly alter the presynaptic second messenger system that influences (Na^+^, K^+^)-ATPase activity. On the other hand the lesions had a much greater effect on performance than old age alone did ([@b94]).

Little is known about the activity of Mg^2+^-ATPase in old age, an enzyme that is of primary importance in phosphorylation reactions and the maintenance of high brain intracellular Mg^2+^. Its change can control rates of protein synthesis and growth of the cell ([@b84]). Decreased Mg^2+^-ATPase activity in the frontal cortex of old age rats was reported by [@b39].

Oxidative stress has been implicated in aging and age-related neurodegenerative diseases ([@b5]; [@b97]; [@b111]) and the proposal of the "free radical theory of aging" ([@b41]). Impaired total antioxidant capacity in different structures from aged rat brain was observed by [@b91]. A decrease of the total antioxidant status in the brain of old male rats has been observed by [@b14].

Based on the aforementioned selegiline study in aged rats, the foreseen trend of combining drugs with a different mechanism of action in AD therapy ([@b115]; [@b105]; [@b22]; [@b40]; [@b97]) and since multiple factors contribute to AD pathology ([@b106]; [@b62]) we decided to investigate the effect of the combination of the two agents, rivastigmine and selegiline, on brain TAS, AChE, (Na^+^, K^+^)-ATPase, Mg^2+^-ATPase activities and on cognitive capacity of aged rats. We also considered evaluating the possibility of correlations between biochemical and behavioral data. It should be mentioned that there were no previous in vivo data about the effect of a) rivastigmine alone on the activities of brain (Na^+^, K^+^)-ATPase, Mg^2+^-ATPase or TAS. and b) rivastigmine plus selegiline combined administration on all the biochemical and behavioral parameters studied.

Materials and methods
=====================

Animals
-------

Fifty two (52) aged male Wistar rats (24 months old) and 485 ± 23 g BW were used. A group of 11 adult rats (8 months old) and 391 ± 12 g BW was also used as an adult control. The rats were housed five or six in a cage at a constant room temperature (22 ± 1 °C) under a 12-h light: 12-h dark (light 08:00--20:00 h) cycle. Food and water were provided *ad libitum*. Animals were cared for in accordance with the principles of the *Guide for the Care and Use of Experimental Animals* ([@b19]).

Drugs in vivo administration
----------------------------

Rats were divided into five groups, according to the procedure followed in the object recognition test: 1) Group (R) was treated with rivastigmine (0.3 mg kg^−1^ rat day^-1^ ip) for 36 consecutive days, 2) Group (S) was treated with selegiline (0.25 mg kg^−1^ rat day^−1^ im) for the same period, 3) Group (R + S) was treated with the combination of the two drugs at the doses and way of administration mentioned before for each drug separately and for the same period of time, 4) a group was treated with equal volumes (0.5 ml) of NaCl 0.9% ip (aged control group) and 5) a group was also treated with equal volumes (0.5 ml) of NaCl 0.9% ip (adult control group) for every of the 36 consecutive days.

Tissue preparation
------------------

Animals were sacrificed by decapitation (right after the last performance test and 90 minutes after the last drug administration) and the whole brain was rapidly removed. The tissue was homogenized and centrifuged as described earlier ([@b103]; [@b3]). In the resulting supernatant, the protein content was determined according to the method of [@b63] and the enzyme activities and TAS were evaluated.

Determination of enzyme activities
----------------------------------

AChE activity was determined according to [@b31] and (Na^+^, K^+^)-ATPase, Mg^2+^-ATPase activities according to [@b12]. The enzyme reaction mixture and assay conditions of these enzyme activities were previously described in detail ([@b103]; [@b3]).

Determination of brain total antioxidant status
-----------------------------------------------

TAS was evaluated in each fresh homogenized rat brain. The total antioxidant capacity was measured spectrophotometrically by a commercial kit (Randox Laboratories Ltd., Cat. No. NX2332) as previously reported ([@b103]). 2,2′-Azino-di-\[3-ethylbenzthiazoline sulphonate\] (ABTS) was incubated with a peroxidase (metmyoglobin) and H~2~O~2~ in order to produce the radical cation ABTS^+^. The latter had a relatively stable blue-green color, which was measured at 600 nm. Inhibited values of TAS reflect the increase of brain free radical production whereas stimulated TAS values show the decrease of free radical production and the protective antioxidant effect of the drug in the brain.

Cognitive capacities tests
--------------------------

Cognitive capacities were evaluated using two different tasks: object recognition test (ORT) and passive avoidance conditioned response (PA). The ORT was carried out according to the procedure described by Vannucchi and colleagues ([@b32]; [@b87]; [@b107]). The apparatus was an open white polyvinylchloride arena (70 × 60 × 30 cm^3^) illuminated by a 75 W lamp suspended 50 cm above the arena. The objects to be distinguished were made of polyvinylchloride, grey-colored and were in two different shapes: cubes (8 × 8 cm^2^ side) or pyramids (8 cm height). Apparently they had no significance for the rats. For the procedure, the rat was submitted to a session of two trials, each of which had a 5-min duration. The intertribal interval (ITI) was 60 min. In the first trial (T1) two identical objects were presented in two opposite corners of the box and the amount of time spent by each animal for the object exploration was recorded. Exploration was considered to be directing the nose at a distance \<2 cm to the object and/or touching it with the nose. During the second trial (T2), one of the objects presented in T1 was replaced by a new (differently-shaped) one. To reduce place preference effects, the positions of the two different objects were randomly changed during T2 for each rat. The times spent on exploration of the familiar (F) and new (N) object during T2 were recorded separately and a discrimination index (D) was calculated (N - F/N + F). An animal was defined as impaired if the D was \<0.20. This procedure took place twice for each animal. The first session was one day before the beginning of drugs administration. Among the 52 aged rats studied, 42 (81%) showed impaired performances with a D \<0.10, four rats were unimpaired (D \<0.50), while six rats were discarded because they did not explore. The 42 impaired aged rats were subdivided into the four aforementioned groups: Aged control group (10 rats), Group (R) (10 rats), Group (S) (11 rats), and Group (R + S) (11 rats). Among the 11 adult rats studied none was discarded, as all of them sufficiently explored. The second session was on the 34th day of the drugs administration, in order to evaluate the cognitive capacity of the animals practically at the end of the experiment. The task took place one hour after the drugs' administration.

The passive avoidance training was started 24 h after the last object recognition session. It was carried out according to the procedure described by [@b80] with some modifications (the testing trial took place 24 h after the training trial and not 72 h after it) and consisted of two trials. The passive avoidance box had a light and a dark compartment of equal size, which were separated by a sliding guillotine door. During the first trial (training trial), which took place at the 35th day of drugs administration, the rats were placed in the light compartment. Thirty seconds later the door was opened. After the rat entered the dark compartment, the door was closed and a foot shock of 1.0 mA (3 s) was given. The latency to enter the dark compartment was measured (360 s maximum latency). During the second trial (testing trial), which took place on the 36th day of drugs administration (last day of the experiment), the rat was placed in the light compartment again and the latency to enter the dark compartment was measured. Passive avoidance most likely involves both working memory and reference memory ([@b71]).

Statistical analysis
--------------------

The biochemical data were analyzed by a two-tailed Student's t-test. The object recognition data were analyzed by a nonparametric Mann-Whitney test and the passive avoidance data were analyzed by an one-way ANOVA test and a post-hoc test (Bonferroni test).

Drugs
-----

Rivastigmine; Novartis Ltd., Basle, Switzerland. Selegiline; Sigma-Aldrich. St. Louis, MO, USA.

Results
=======

Total antioxidant status (TAS)
------------------------------

Group (S) (received selegiline) showed a significant increase in TAS compared with the control group of aged rats (+30%, P \< 0.001, t~value~ = 9.66). Groups (R) (received rivastigmine) and (R + S) (received rivastigmine + selegiline) did not show any difference in comparison to the aged control group (t~values~ = 0.48 and 1.13 respectively). TAS was significantly decreased in rivastigmine + selegiline-treated rats compared with selegiline-treated rats (-21%, P \< 0.001, t~value~ = 16.66) ([Figure 1](#fig1){ref-type="fig"}).

![Effects of rivastigmine, selegiline, and rivastigmine + selegiline on brain antioxidant status (TAS). TAS values were determined in each homogenized rat whole brain. Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of adult control rats, of selegiline, and of rivastigmine + selegiline indicate the mean ± SE. of eleven independent experiments (eleven rats). The average value of each experiment arises from three determinations.\
**Notes:** NS, nonstatistical significance; \*\*\*P \< 0.001 compared with aged control group; \#\#\#P \< 0.001 compared with selegiline-treated group.](ndt0404-687-01){#fig1}

Brain AChE activity
-------------------

Selegiline-treated rats revealed a significant increase in brain AChE activity compared with the aged control rats (+25%, P \< 0.001, t~value~ = 10.73). Contrary to this, rivastigmine alone and rivastigmine+selegiline co-administration induced a significant decrease in brain AChE activity in comparison to the aged saline-treated rats (−20%, P \< 0.001, t~value~ = 10.80 and −22%, P \< 0.001, t~value~ = 11.08, respectively). Brain AChE activity was also significantly decreased in rats treated with rivastigmine+selegiline in comparison to the rats treated with selegiline alone (-38%, P \< 0.001, t~value~ = 36.99) ([Figure 2](#fig2){ref-type="fig"}).

![Effects of rivastigmine, selegiline, and rivastigmine + selegiline on brain AChE activity. AChE activities were determined in each homogenized rat whole brain. Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of adult control rats, of selegiline and of rivastigmine + selegiline indicate the mean ± SE of eleven independent experiments (eleven rats). The average value of each experiment arises from three determinations.\
**Notes:** \*\*\*P \< 0.001 compared with aged control group; \#\#\#P \< 0.001 compared with selegiline-treated group.](ndt0404-687-02){#fig2}

(Na^+^, K^+^)-ATPase activity
-----------------------------

(Na^+^, K^+^)-ATPase activity was significantly increased in rats which received selegiline (+50%, P \< 0.001, t~value~ = 11.08) or rivastigmine (+36%, P \< 0.001, t~value~ = 8.48) in comparison with aged saline-treated rats. Furthermore, in the case of rivastigmine+selegiline co-administration, an additive action of the two drugs concerning the increase of (Na^+^, K^+^)-ATPase activity was revealed in comparison to the aged control group (+88%, P \< 0.001, t~value~ = 15.62). A significant increase of (Na^+^, K^+^)-ATPase activity in (R+S) group in comparison to the (S) group was also observed (+25%, P \< 0.001, t~value~ = 14.84) ([Figure 3](#fig3){ref-type="fig"}).

![Effects of rivastigmine, selegiline, and (rivastigmine + selegiline) on brain (Na^+^, K^+^)-ATPase activity. (Na^+^, K^+^)-ATPase activities were determined in each homogenized rat whole brain. Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of adult control rats, of selegiline and of rivastigmine + selegiline indicate the mean ± SE of eleven independent experiments (eleven rats). The average value of each experiment arises from three determinations.\
**Notes:** \*\*\*P \< 0.001 compared with aged control group; \#\#\#P \< 0.001 compared with selegiline-treated group.](ndt0404-687-03){#fig3}

Mg^2+^-ATPase activity
----------------------

Mg^2+^-ATPase activity was significantly increased in (R) group and (R + S) group in comparison to the aged control group (+40%, P \< 0.001, t~value~ = 8.78 and +23%, P \< 0.001, t~value~ = 8.15, respectively), while no difference in Mg^2+^-ATPase activity was observed in the selegiline-treated group (t~value~ = 0.55). The rivastigmine+selegiline co-administration induced a significant increase in Mg^2+^-ATPase activity in comparison to selegiline alone administration (+26%, P \< 0.001, t~value~ = 13.45) ([Figure 4](#fig4){ref-type="fig"}).

![Effects of rivastigmine, selegiline, and (rivastigmine + selegiline) on brain Mg^++^-ATPase activity. Mg^++^-ATPase activities were determined in each homogenized rat whole brain. Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of adult control rats, of selegiline and of rivastigmine + selegiline indicate the mean ± SE of eleven independent experiments (eleven rats). The average value of each experiment arises from three determinations.\
**Notes:** NS, nonstatistical significance; \*\*\*P \< 0.001 compared with aged control group; \#\#\#P \< 0.001 compared with selegiline-treated group.](ndt0404-687-04){#fig4}

Object recognition test
-----------------------

In the object recognition test the discrimination between familiar and novel objects was significantly better in selegiline-treated (P \< 0.001, Mann-Whitney U = 4.50) or rivastigmine-treated rats (P \< 0.001, Mann-Whitney U = 0.50) than aged saline-treated rats. There was no statistically significant difference in the discrimination index between (R + S) group (Mann-Whitney U = 12.00) and aged control group ([Figure 5](#fig5){ref-type="fig"}).

![Effects of rivastigmine, selegiline, and rivastigmine + selegiline on object recognition task on day 34 of the administration of the drugs. Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of adult control rats, of selegiline and of rivastigmine + selegiline indicate the mean ± (SE) of eleven independent experiments (eleven rats).\
**Notes:** NS, nonstatistical significance; \*\*P \< 0.05; \*\*\*P \< 0.001 compared with aged control group.](ndt0404-687-05){#fig5}

Passive avoidance procedure
---------------------------

In passive avoidance procedure, during the training trial the mean latency (42 s) was not significantly different among the groups. During the testing trial, a significantly better performance was observed in groups (R)(F = 59.18) and (S)(F = 59.18), in comparison with the aged control group. The combination of rivastigmine + selegiline did not show any statistically significant difference from the aged control group (F = 59.18) ([Figure 6](#fig6){ref-type="fig"}). These results are similar to those of the object recognition test.

![Effects of rivastigmine, selegiline, and rivastigmine + selegiline on passive avoidance test in testing trial (day 36 of the administration of the drugs). Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of adult control rats, of selegiline, and of rivastigmine + selegiline indicate the mean ± SE of eleven independent experiments (eleven rats).\
**Notes:** NS, nonstatistical significance; \*\*\*P \< 0.001 compared with aged control group.](ndt0404-687-06){#fig6}

Adult versus aged rats
----------------------

An increase of total antioxidant status (TAS) was observed in adult control group compared with the aged control group (+20%, P \< 0.001, t~value~ = 5.62) ([Figure 1](#fig1){ref-type="fig"}). Adult controls revealed a significant increase in brain AChE activity compared with the aged control rats (+39%, P \< 0.001, t~value~ = 25.07) ([Figure 2](#fig2){ref-type="fig"}). (Na^+^, K^+^)-ATPase activity was significantly decreased in adult controls compared to the aged control group (−24%, P \< 0.001, t~value~ = 5.17) ([Figure 3](#fig3){ref-type="fig"}). Mg^2+^-ATPase activity was significantly increased in adult control group in comparison with the aged control group (+34%, P \< 0.001, t~value~ = 10.69) ([Figure 4](#fig4){ref-type="fig"}). In the object recognition test the adult control group performed significantly better than the aged one (P \< 0.05, Mann-Whitney U = 9.00) ([Figure 5](#fig5){ref-type="fig"}). In passive avoidance procedure, during the testing trial, a better performance was observed in adult control group in comparison with the aged control group (F = 59.18) ([Figure 6](#fig6){ref-type="fig"}).

Discussion
==========

We have examined: (a) the long term effects of rivastigmine in combination with selegiline on the activity of AChE, (Na^+^, K^+^)-ATPase, Mg^2+^-ATPase and TAS in whole brain homogenate of aged male rats, as well as their cognitive capacity; and (b) the possible relationship between biochemical and behavioral findings.

Rivastigmine decreased AChE activity in the aged rat whole brain as expected ([@b2]; [@b20]), in comparison with the adult and aged control group ([Figure 2](#fig2){ref-type="fig"}). It is worth noticing that the adult control has the highest value of AChE activity. On the contrary, selegiline alone significantly increased AChE activity in the aged rats. The latter data are in accordance with other studies ([@b79]; [@b56]; [@b116]; [@b14]). In particular [@b116] found increased AChE activity in the rat brain following 1 week of selegiline administration and [@b56] observed increased AChE activity in certain brain areas of adult monkeys following selegiline treatment with most pronounced effect in the region of hippocampus. Enhanced AChE activity in rat hippocampus was also reported by [@b79] following intracerebroventricular administration of selegiline. In the combination of rivastigmine + selegiline, the rivastigmine effect appears to prevail leading to a significant decrease in brain AChE activity compared with the (S) group and with the two control groups ([Figure 2](#fig2){ref-type="fig"}).

Reduced activity of AChE and ChAT has been reported in the cortex and the hippocampus of AD patients ([@b36]) and is also associated with the decline in cognitive function ([@b25]). In our study, brain AChE activity was decreased in aged rats, in parallel with the object recognition and passive avoidance performance ([Figure 2](#fig2){ref-type="fig"}, [5](#fig5){ref-type="fig"}-[6](#fig6){ref-type="fig"}). On the contrary, while rivastigmine (as expected) decreases AChE activity, it improves cognitive performance. Here a question could arise as to whether the 20% inhibition of AChE by rivastigmine is enough to produce an increase in cortical and hippocampal ACh release. Many studies in the literature using different doses of rivastigmine revealed a strong correlation between AChE inhibition and ACh increase in the aforementioned rat brain areas ([@b101]; [@b17]; Kozaka 1999; [@b102]; [@b86]; [@b1]; [@b59]). Considering the improved performance in learning and memory tests by rivastigmine group of rats, we suggest that this percentage reduction of AChE was enough for the needed cortical and hippocampal ACh release. Also, while selegiline increases AChE activity, it improves cognitive performance. In the combination of rivastigmine + selegiline treatment no improved performance was observed despite decreased AChE activity. Concerning AChE activity, it is obvious that the mechanism by which a better performance is attained in the behavioral tests following administration of rivastigmine or selegiline (given separately) is different. Rivastigmine is used in AD according to the cholinergic hypothesis, which improves or delays to some extent the deterioration of AD patients ([@b2]; [@b20]; [@b6]). At the same time selegiline was found to improve cognitive function after long-term administration in rats ([@b52]) and to slow the progression of AD in man ([@b83]). In our past experiments, although selegiline increased AChE activity, it improved avoidance performance ([@b14]). The present study also shows improvement in both learning parameters. One can only speculate that the increased expression of ChAT and AChE in the hippocampus by selegiline ([@b79]) may have also caused an increase of ACh (which is mainly involved in learning and memory) provided that ACh release is not affected by selegiline in the hippocampus ([@b53]; [@b74]; [@b26]). Furthermore, it has been reported that increases in dopamine levels enhance a compensatory release of acetylcholine in the frontal cortex ([@b73]; [@b90]) and that the forebrain dopaminergic system is related to cognitive function ([@b65]; [@b78]). According to [@b55] selegiline (given in a dose of 2 mg/kg) completely restores ChAT activity deficits in simian immunodeficiency infection in brain regions containing cholinergic neurons. It is unclear whether selegiline acted on the expression of ChAT (directly or through increased dopamine availability) thereby increasing protein synthesis or as a neuroprotective agent on cholinergic and other neurons through its antioxidant effects ([@b50]). In addition, [@b4] reported that AChE induced long-term potentiation in hippocampal pyramidal neurons, suggesting that AChE per se might enhance cognitive performance. We could refer to [@b89], [@b88] hypotheses on the design of agents that could enhance the neuronal AChE activity in order to delay the degeneration of brain AChE system in the development of dementia and AD. Furthermore, [@b37] has come to a similar conclusion concerning the cholinergic hypothesis in its present form and the use of AChE-inhibitors. According to [@b47], the scientific basis for recommendations of cholinesterase inhibitors for the treatment of Alzheimer's disease is questionable because of flawed methods and small clinical benefits; even though the AChE inhibitors and memantine is the only available drug treatment until now ([@b57]; [@b9]).

In any case, one cannot exclude the neuronal adaptations to diminished synaptic ACh metabolism in acetylcholinesterase knockout mice ([@b108]) and the possibility of AChE involvement of the senile plaque ([@b77]; [@b16]).

The synaptic plasma membrane enzyme (Na^+^, K^+^)-ATPase is very important for neurotransmission-neuronal excitability ([@b85]), metabolic energy production ([@b67]), the uptake and release of catecholamines ([@b11]; [@b96]), serotonin ([@b44]), glutamate ([@b58]), and at least partial ACh release ([@b69]). Studies suggest that (Na^+^, K^+^)-ATPase might play a role on memory formation ([@b27]) and that it is a particular age-related enzyme ([@b39]).

Increased activity of whole brain (Na^+^, K^+^)-ATPase was observed after the administration of rivastigmine, selegiline, or their combination ([Figure 3](#fig3){ref-type="fig"}). In the latter, the effect seems to be additive. Similar results concerning increased enzyme activity in aged and selegiline-treated rats were observed in our previous studies ([@b104]; [@b14]).

[@b28] reported a decreased overall (Na^+^, K^+^)-ATPase enzyme activity in the amyloid containing hippocampi of the APP + PSI mice. They also reported absence of (Na^+^, K^+^)-ATPase staining in the zone surrounding congophilic plaques, which was occupied by dystrophic neurites and that cerebral (Na^+^, K^+^)-ATPase can be directly inhibited by high concentrations of soluble Ab. It has been also reported that (Na^+^, K^+^)-ATPase protein levels are decreased in AD tissue but not in normal aged tissue ([@b42]; [@b61]). Our study deals with normally aged rats in which (Na^+^, K^+^)-ATPase activity was actually and significantly increased in comparison with the adult control, but their performance was decreased. Considering that ouabain, a (Na^+^, K^+^)-ATPase inhibitor, has been shown to impair memory consolidation, it was suggested that increasing (Na^+^, K^+^)-ATPase activity and maintaining ionic balance of the neurons may benefit AD patients by delaying the onset of neuritic dystrophia and memory dysfunction ([@b110]; [@b66]).

In our study with aged rats, in spite of enhanced (Na^+^, K^+^)-ATPase activity in comparison with the adult control, the aged animals had an impaired learning performance. In addition, in the (S) and (R) groups (with enhanced (Na^+^, K^+^)-ATPase activity) a better learning performance was observed, while in the combination group (in which an even higher increase of (Na^+^, K^+^)-ATPase activity was observed) no statistically significant difference in its learning performance was noticed ([Figures 3](#fig3){ref-type="fig"}, [5](#fig5){ref-type="fig"}-[6](#fig6){ref-type="fig"}). According to all the above, we come to the conclusion that increased (Na^+^, K^+^)-ATPase activity is not relevant to the cognition enhancement by rivastigmine, selegiline, or their combination, at least not under our experimental conditions.

The role of Mg^2+^-ATPase is to maintain high brain intracellular Mg^2+^, the changes of which can control rates of protein synthesis and growth of the cell ([@b84]). Decreased Mg^2+^-ATPase activity in the frontal cortex of old age rats was reported by [@b39]. In our experiments, decreased Mg^2+^-ATPase activity was observed in old rats in parallel with decreased learning performance. Mg^2+^-ATPase activity was found to be higher in the groups (R), (R+S) and young controls ([Figure 4](#fig4){ref-type="fig"}). Consequently, a positive association between increased Mg^2+^-ATPase activity and learning performance could be supported for rivastigmine, while selegiline improves learning performance without affecting brain Mg^2+^-ATPase activity. In the combination, although there was an increased Mg^2+^-ATPase activity, no significant improvement in the behavioral parameters was observed. It is likely that the addition of selegiline in some way reduced the effect of rivastigmine alone on Mg^2+^-ATPase activity and this could influence the better performance of rivastigmine alone. This association is questionable as well.

The observed decrease of brain TAS during aging is in accordance with our previous studies ([@b104]; [@b14]) and is associated with the decreased learning performance (object recognition and passive avoidance test) ([Figures 1](#fig1){ref-type="fig"}, [5](#fig5){ref-type="fig"}-[6](#fig6){ref-type="fig"}). Although rivastigmine administration in aged rats did not affect TAS, it resulted in a better learning performance. On the contrary, selegiline administration (as previously shown by [@b14]) increased TAS and this effect can be linked with better learning performance ([Figures 1](#fig1){ref-type="fig"}, [5](#fig5){ref-type="fig"}-[6](#fig6){ref-type="fig"}). Similar results were also reported by [@b49]: increase of spatial memory performance in aged male rats after selegiline administration for 21 days, suppression of lipid peroxidation, and alleviation of the age-related decrease of the number of neurons in the hippocampus. Improved performance after long term selegiline administration has also been observed by [@b53] and other investigators ([@b74]; [@b26]). In the combination of rivastigmine + selegiline no statistically significant differences were observed either in TAS or in learning performance although there is a tendency in the object recognition test ([Figures 1](#fig1){ref-type="fig"}, [5](#fig5){ref-type="fig"}). It is rather obvious that selegiline effect on TAS is blunted by rivastigmine ([Figures 1](#fig1){ref-type="fig"}, [5](#fig5){ref-type="fig"}-[6](#fig6){ref-type="fig"}). Selegiline is a MAO-B inhibitor enhancing dopamine levels and after its chronic administration long-term postsynaptic changes have most likely occurred. The dopaminergic activity for example could be inhibitory to cholinergic striatal inter neurons. This probably explains the negation of the behavioral effects of rivastigmine by selegiline. In the study of [@b82] the chronic treatment of rats with ladostigil, a novel drug derived from the combination of rivastigmine and a MAO-B inhibitor rasagiline, resulted in activation of both striatal cholinergic and dopaminergic activity, attenuation of stereotyped motor behavior and maintenance of normal spontaneous motor performance. However, [@b99] (donepezil and selegiline in acute and high dose in scopolamine + chlorophenylalanine -- induced memory deficits) and [@b29] (tacrine and selegiline with electroencephalographic and behavioral evidence) who used totally different experimental protocols observed that the combination of selegiline and another AChE inhibitor (donepezil or tacrine) acted synergistically and improved reversal of memory impairment in rats.

Conclusions
===========

The overall analysis of our data revealed that rivastigmine when given alone decreases AChE, does not influence TAS, increases (Na^+^, K^+^)-ATPase and Mg^2+^-ATPase activities, and improves learning performance of the aged rats. In the combination the effect of rivastigmine on AChE activity (reduced) appears to prevail that of selegiline (increased) and the result is reduced activity of AChE. In the case of TAS, although rivastigmine when given alone, did not affect TAS, in the combination decreases the enhanced by selegiline old rat brain TAS and increases Mg^2+^-ATPase activity. There is also an improved learning performance by each drug alone, but not in the combination. It is obvious that the better performance of rivastigmine and selegiline given separately in the object recognition and in the passive avoidance test is attributed to a different mechanism of action: Selegiline possibly acts through its antioxidant effect and increased levels of catecholamines and rivastigmine by its anticholinesterase activity and increased levels of acetylcholine. Finally, the combination of the two drugs does not appear to be beneficial for the declining memory of aged rats at least not under our experimental conditions. Reduced Mg^2+^-ATPase activity is correlated with old age and reduced learning performance. Rivastigmine is correlated with increased Mg^2+^-ATPase activity and increased learning performance. Decreased TAS is correlated with old age and in parallel with decreased performance. Selegiline is correlated with increased TAS and increased performance. In the combination, rivastigmine+selegiline did not affect either TAS or learning performance. Several transmitter systems can probably have a primary function in some cognitive processes and among which are the cholinergic and dopaminergic ones, but the extent of interactions is difficult to be elucidated. The subject therefore requires further investigation.

To our knowledge this is the first report about a) the effect of rivastigmine on (Na^+^, K^+^)-ATPase and Mg^2+^-ATPase activities, TAS, on rat whole brain and b) the combined administration of rivastigmine and selegiline and its effect on all the studied parameters.
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